We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HEI:NYSEHeico Corporation Analysis

Data as of 2026-03-13 - not real-time

$288.45

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

HEICO’s stock is trading well below its short‑ and long‑term moving averages (20‑day SMA ≈ $324, 50‑day SMA ≈ $332, 200‑day SMA ≈ $320) and the RSI sits near 31, indicating a technically oversold condition. The MACD remains bearish, with the line under the signal, and volume has been trending down, while 30‑day volatility is elevated at over 40 %. Fundamentally, the company delivers solid top‑line growth (≈14 % YoY revenue increase) and healthy margins (gross ≈ 40 %, operating ≈ 22 %, profit ≈ 15 %), yet valuation metrics are stretched – a trailing P/E of 57 versus an industry average of 29 and a DCF‑derived fair value around $107 suggest the market is pricing in significant premium.
Recent earnings beat headline estimates but revealed underlying weaknesses that triggered a 12 % share drop, and the balance sheet carries a high debt load (Debt‑to‑Equity ≈ 50 %) offset by modest cash. Nonetheless, the company’s low dividend payout (≈5 % of earnings) and strong free cash flow underpin dividend sustainability, while acquisition momentum and a record backlog point to potential margin improvement in the coming quarters.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent earnings disappointment and 12% price drop
  • Technical oversold signal with high volatility
  • Elevated valuation relative to fundamentals

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong revenue growth and margin expansion outlook
  • Analyst consensus target price implying ~28% upside
  • Continued acquisition activity and record backlog

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Durable demand in aerospace & defense sector
  • Robust cash generation supporting dividend and debt reduction
  • Diversified product portfolio reducing business cyclicality

Key Metrics & Analysis

Financial Health

Revenue Growth14.40%
Profit Margin15.38%
P/E Ratio57.1
ROE16.57%
ROA7.85%
Debt/Equity49.70
P/B Ratio8.9
Op. Cash Flow$909.8M
Free Cash Flow$690.8M
Industry P/E29.1

Technical Analysis

TrendNeutral
RSI30.9
Support$285.52
Resistance$354.70
MA 20$323.64
MA 50$332.27
MA 200$319.81
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair Value$106.65
Target Price$371.50
Upside/Downside28.79%
GradeOvervalued
TypeGrowth
Dividend Yield0.08%

Risk Assessment

Beta0.79
Volatility41.11%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.